These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30205050)

  • 1. Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner.
    Mancini A; Xavier-Magalhães A; Woods WS; Nguyen KT; Amen AM; Hayes JL; Fellmann C; Gapinske M; McKinney AM; Hong C; Jones LE; Walsh KM; Bell RJA; Doudna JA; Costa BM; Song JS; Perez-Pinera P; Costello JF
    Cancer Cell; 2018 Sep; 34(3):513-528.e8. PubMed ID: 30205050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-specific loss of
    Amen AM; Fellmann C; Soczek KM; Ren SM; Lew RJ; Knott GJ; Park JE; McKinney AM; Mancini A; Doudna JA; Costello JF
    Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33758097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GABP couples oncogene signaling to telomere regulation in TERT promoter mutant cancer.
    McKinney AM; Mathur R; Stevers NO; Molinaro AM; Chang SM; Phillips JJ; Costello JF
    Cell Rep; 2022 Sep; 40(12):111344. PubMed ID: 36130485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.
    Bell RJ; Rube HT; Kreig A; Mancini A; Fouse SD; Nagarajan RP; Choi S; Hong C; He D; Pekmezci M; Wiencke JK; Wrensch MR; Chang SM; Walsh KM; Myong S; Song JS; Costello JF
    Science; 2015 May; 348(6238):1036-9. PubMed ID: 25977370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conserved features of TERT promoter duplications reveal an activation mechanism that mimics hotspot mutations in cancer.
    Barger CJ; Suwala AK; Soczek KM; Wang AS; Kim MY; Hong C; Doudna JA; Chang SM; Phillips JJ; Solomon DA; Costello JF
    Nat Commun; 2022 Sep; 13(1):5430. PubMed ID: 36114166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GABPβ1L Wakes Up TERT.
    Rahme GJ; Gaskell E; Bernstein BE
    Cancer Cell; 2018 Sep; 34(3):358-360. PubMed ID: 30205042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
    Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
    Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
    Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
    Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma.
    Ahmad F; Dixit D; Sharma V; Kumar A; Joshi SD; Sarkar C; Sen E
    Cell Death Dis; 2016 May; 7(5):e2213. PubMed ID: 27148686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers.
    Stern JL; Theodorescu D; Vogelstein B; Papadopoulos N; Cech TR
    Genes Dev; 2015 Nov; 29(21):2219-24. PubMed ID: 26515115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An interaction proteomics survey of transcription factor binding at recurrent TERT promoter mutations.
    Makowski MM; Willems E; Fang J; Choi J; Zhang T; Jansen PW; Brown KM; Vermeulen M
    Proteomics; 2016 Feb; 16(3):417-26. PubMed ID: 26553150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends.
    Yuan X; Dai M; Xu D
    Cancer Lett; 2020 Nov; 493():1-9. PubMed ID: 32768523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.
    Diplas BH; He X; Brosnan-Cashman JA; Liu H; Chen LH; Wang Z; Moure CJ; Killela PJ; Loriaux DB; Lipp ES; Greer PK; Yang R; Rizzo AJ; Rodriguez FJ; Friedman AH; Friedman HS; Wang S; He Y; McLendon RE; Bigner DD; Jiao Y; Waitkus MS; Meeker AK; Yan H
    Nat Commun; 2018 May; 9(1):2087. PubMed ID: 29802247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmable base editing of mutated TERT promoter inhibits brain tumour growth.
    Li X; Qian X; Wang B; Xia Y; Zheng Y; Du L; Xu D; Xing D; DePinho RA; Lu Z
    Nat Cell Biol; 2020 Mar; 22(3):282-288. PubMed ID: 32066906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TERT promoter mutations in primary and secondary glioblastomas.
    Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
    Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume.
    Aquilanti E; Kageler L; Watson J; Baird DM; Jones RE; Hodges M; Szegletes ZM; Doench JG; Strathdee CA; Figueroa JRMF; Ligon KL; Beck M; Wen PY; Meyerson M
    Neuro Oncol; 2023 Jul; 25(7):1275-1285. PubMed ID: 36694348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma.
    Pierini T; Nardelli C; Lema Fernandez AG; Pierini V; Pellanera F; Nofrini V; Gorello P; Moretti M; Arniani S; Roti G; Giovenali P; Lupattelli M; Metro G; Molica C; Castrioto C; Corinaldesi R; Laurenti ME; Ascani S; Mecucci C; La Starza R
    Acta Neuropathol Commun; 2020 Aug; 8(1):145. PubMed ID: 32843091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERT Promoter Mutations Enhance Telomerase Activation by Long-Range Chromatin Interactions.
    Min J; Shay JW
    Cancer Discov; 2016 Nov; 6(11):1212-1214. PubMed ID: 27807101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomerase as a therapeutic target in glioblastoma.
    Aquilanti E; Kageler L; Wen PY; Meyerson M
    Neuro Oncol; 2021 Dec; 23(12):2004-2013. PubMed ID: 34473298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.